Search results
Apr 15, 2022 · Patent number: 11963982. Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid. Type: Grant. Filed: November 8, 2019. Date of Patent: April 23, 2024. Assignee: EDITAS MEDICINE, INC.
People also ask
What patents does Editas Medicine have?
Does Editas have a patent for CRISPR/Cas9 editing?
Who is Editas Medicine?
Feb 28, 2022 · Editas Medicine’s patents broadly cover CRISPR/Cas9 and CRISPR/Cas12a gene editing in all human cells. Successfully editing this cell type is essential to making CRISPR-based medicines.
Feb 28, 2022 · The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene editing technology.
Feb 28, 2022 · Editas Medicine’s patents broadly cover CRISPR/Cas9 and CRISPR/Cas12a gene editing in all human cells. Successfully editing this cell type is essential to making CRISPR-based medicines.
Dec 13, 2023 · After receiving the FDA greenlight for its sickle cell disease (SCD) gene therapy, Vertex Pharmaceuticals is paying up to $100 million—plus potential licensing fees—for rights to Editas...
- Gabrielle Masson
Dec 14, 2023 · Days after winning U.S. approval of the first CRISPR gene-editing medicine, Vertex Pharmaceuticals is clearing up potential intellectual property questions about the sickle cell disease therapy by signing a deal with Editas Medicine.
Apr 18, 2024 · Editas Medicine has been granted a patent for methods and compositions to enhance the compatibility of donor cells for transplantation. The invention involves modifying immunogenicity genes in cells, such as HLA genes, to reduce cell surface expression of specific proteins, making them suitable for transplantation.
